EU Group Wants Greater Reciprocity As Chinese Foreign Deals Expand
Executive Summary
Ahead of last weekend’s G20 meeting in Hangzhou, a powerful EU business group in China called for increased reciprocity over major M&A deals, suggesting that closer European scrutiny may come if China does not further open its doors. Drug price pressures in China were also flagged up as a major European concern in a new position paper.
You may also be interested in...
China Fast-Tracks Multiple HCV Drugs With Access In Mind
All eyes on a list of selected oral hepatitis C drugs that are expected to win out in China's notoriously lengthy approval battle, amid a potentially huge opening as Chinese HCV patients switch from interferon to all oral therapies.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.